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INTRODUCTION
Endometrial cancer is the sixth most common can-
cer in women worldwide, with an estimated
288,387 new cases in 2008, and a standardized in-
cidence rate of 8.2 per 100,000 women. While the
global burden, in terms of the number of cases, is
evenly distributed between less developed and
more developed regions, incidence and mortality
rates are higher in more developed regions.1
North America and Western Europe show some
of the highest standardized incidence rates (grea-
ter than 10 per 100,000 women), with the lowest
Abstract
Objective: To evaluate the preoperative endometrial cancer risk as
a guidance to choose the type of surgical approach based on Euro-
pean Society for Medical Oncology guideline (2009).
Method: Cross-sectional study involved 73 endometrial cancer pa-
tients of Dr. Cipto Mangunkusumo Hospital, from January 2006 to
December 2012 which obtained from medical record. The inclusion
criteria were endometrial cancer patients with complete D&C, ul-
trasonographic, and postoperative histopathological reports. Endo-
metrial cancer risk of recurrence was classified according to ESMO
2009 and final diagnosis and stage based on FIGO.
Result: From 405 patients, only 73 patients had complete reports.
Most of the them were postmenopausal (54.8%), non-nulliparity
(79.9%), and obese (49.5%) women. According to risk of recurrence
stratification, low, intermediate and high risk were found in 12 pa-
tients, 27 patients, and 34 patients. Based on FIGO, there were
60.2% early and 39.8% advanced stage. In high risk group, rates of
advanced stage were prominent compared to other groups. There
were 38.3% patients with postoperative positive lymph nodes me-
tastases.
Conclusion: Most of the endometrial cancer patients were preop-
eratively diagnosed as high risk. The commonest stage after surgical
examination were IIIC. High risk of recurrence showed more posi-
tive lymph node compared to low or intermediate risk. Result of pre-
operative histopathological and myometrial invasion compared to
postoperative results were showed to be inconsistent. Patients with
≥ 2 myometrial invasion had more positive lymph nodes metasta-
ses. Endometrial cancer risks compared to FIGO stage showed the
higher the risk, the more advanced the stage were.
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Abstrak
Tujuan: Untuk mengevaluasi risiko kanker endometrium berdasar-
kan klasifikasi European Society for Medical Oncology (2009) dengan
hasil pemeriksaan histopatologi pascaoperatif.
Metode: Studi potong lintang dengan 73 pasien kanker endometrium
di Rumah Sakit Dr. Cipto Mangunkusumo dari Januari 2006 sampai
Desember 2012 yang didapat dari rekam medis. Kriteria inklusi terdiri
dari pasien kanker endometrium yang mempunyai hasil histopatologi
dilatasi dan kuretase dan ultrasonografi praoperatif, dan histopa-
tologi pascaoperatif yang lengkap. Klasifikasi risiko rekurensi kanker
endometrium berdasarkan ESMO 2009 dan diagnosis stadium akhir
berdasarkan FIGO.
Hasil: Dari 405 pasien, hanya 73 pasien yang memiliki data lengkap.
Sebagian besar pasien pascamenopause (54,8%), bukan nuliparitas
(79,9%), dan pasien obesitas (49,5%). Berdasarkan stratifikasi risiko
rekurensi, terdapat 12 pasien risiko rendah, 27 pasien risiko mene-
ngah, dan risiko tinggi 34 pasien. Berdasarkan kriteria FIGO, terdapat
60,2% stadium awal dan 39,8% stadium menengah. Pada kelompok
pasien risiko tinggi, stadium akhir sangat menonjol dibandingkan
kelompok risiko lain. Terdapat 38,3% pasien dengan metastasis positif
pada kelenjar getah bening.
Kesimpulan: Kebanyakan pasien kanker endometrium didiagnosa ri-
siko tinggi. Stadium IIIC paling sering ditemukan setelah pemeriksaan
pascaoperatif. Risiko rekurensi tinggi menunjukkan lebih banyak ke-
lenjar getah bening yang positif dibandingkan risiko rendah ataupun
menengah. Hasil histopatologi dan invasi miometrium praoperatif le-
bih inkonsisten dibandingkan hasil pascaoperatif. Metastasis kelenjar
getah bening lebih banyak ditemukan pada pasien dengan invasi ≥ 2
miometrium. Semakin tinggi risiko kanker endometrium, semakin lan-
jut stadiumnya.
[Maj Obstet Ginekol Indones 2014; 2: 99-105]
Kata kunci: kanker endometrium, kelenjar getah bening, risiko me-
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rates occurring in Asia and Africa.2 Overall, the
mortality incidence ratio of endometrial cancer is
26%, and it was responsible for 73,854 deaths in
2008.1 This cancer rise sharply in occurrence du-
ring the perimenopausal years and peak well after
the menopause.3 Ninety percent of cases occur in
women older than 50 years, and the median age at
diagnosis is 62 years.1-4 Most women are being di-
agnosed because of irregular vaginal bleeding and
roughly 76% of women survive for 5 years.5
Diagnosis of endometrial cancer is confirmed by
endometrial biopsy via dilatation and curettage
(D&C).5 A diagnosis of endometrial cancer must be
obtained before staging or treatment that confirms
the cancer, identifies the histological type and gra-
de.5,6 Treatment strategy is determined by classi-
fed risk of recurrence, which is defined by stage,
histological type, and grade according to European
Society for Medical Oncology (ESMO) risk classifi-
cation 2009. Surgery is the standard treatment for
endometrial cancer patient. Others additional ope-
rative procedures, such as lymphadenectomy and/
or omentectomy are performed based on clinical
stage, histological type, and grade.5-7
Based on histopathology, endometrial cancer is
divided into two categories, type I is endometrioid
tumors which suggested that the multistep carcino-
genicprocess of type 1 endometrial tumors begins
with simple endometrial hyperplasia, progresses to
complex atypia hyperplasia, and then develops into
the precursor lesion, endometrial intraepithelial
neoplasia (EIN). Type 2 or nonendometrioid tu-
mors, encompasses the remaining 10-20% of spo-
radic endometrial tumors. Histologies of type 2 are
uterine papillary serous carcinoma (UPSC), clear-
cell carcinoma and carcinosarcoma.5,8
Myometrial invasion depth is a predictor of re-
currence, and important in the decision making for
adjuvant treatment.9,10 According to the FIGO stag-
ing system, myometrial invasion depth is ex-
pressed as invasion of < 2 of the myometrium and
≥2 of the myometrium.9,11 Preoperative radiologic
testing using ultrasound, computed tomography, or
magnetic resonance imaging is suboptimal in iden-
tifying patients with pelvic or paraaortic nodal me-
tastases and to examine myometrial invasion.12,13
Patients with low risk endometrial cancers or in-
tra operatively assessed with no lymph node me-
tastases are not considered for pelvic and para-aor-
tic lymphadenectomy for surgical staging.14,15
Meanwhile, in intermediate risk patient, the use-
fulness of lymphadenectomy is still debating, and
pelvic lymphadenectomy is not recommended, un-
less for stage IB grade 2 or stage IA grade 3 with
myometrial involvement.5 Para-aortic and iliac
lymphadenectomy is recommended in high risk en-
dometrial cancers.5
The objective of this study is to evaluate pre-
operative endometrial cancer risk of recurrence,
based on dilatation and curettage (D&C) histopa-
thological and ultrasonographic findings, to their
postoperative histopathological findings.
METHODS
This retrospective study was conducted on endo-
metrial cancer patients in Dr. Cipto Mangunku-
sumo General Hospital, Jakarta, Indonesia from
January 2006 until December 2012. Patients’ data
were obtained from medical record consisting age,
menopausal status, parity, BMI status, preoperative
and postoperative histopathological reports, and
ultrasonographic reports. The inclusion criteria of
this study were endometrial cancer patients with
dilatation and curettage (D&C) histopathological
reports, ultrasonographic examination, and post-
operative histopathological reports. Patients with
incomplete histopathological result were excluded
from this study.
BMI status (kg/m2) was defined based on World
Health Organization (WHO) for Asian population
classification.16 Endometrial cancer risk of recur-
rence was classified into low, intermediate, and
high risk according to European Society for Medical
Oncology (ESMO) 2009, based on histological type,
grade, and myometrial invasion.7 Preoperative his-
tological type and grade were obtained by D&C his-
topathological reports. Meanwhile, myometrial in-
vasion depth was obtained by ultrasonographic ex-
amination. Endometrial cancer was stage based on
Federation of Gynecology and Obstetrics (FIGO)
2009 endometrial cancer surgical staging.5
Lymphadenectomy was recommended in high
risk endometrial cancer.5 Lymphadenectomy is re-
commended for intermediate risk, but this can be
considered stage IB grade 2 and stage IA grade 3
with myometrial involvement. Meanwhile, lymph-
adenectomy is not recommended in low risk en-
dometrial cancer.
All data were processed with SPSS 20.0 soft-
ware. The statistical analysis used was a descrip-
tive study of D&C histopathological findings, ultra-
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sonographic examination, and postoperative histo-
pathological result.
RESULT
From 405 patients identified from hospital registry
from January 2002 until December 2012, only 73
of them had complete D&C histopathological re-
ports, ultrasonographic reports, and postoperative
histopathological reports.
Demographic characteristics of patients was
shown in Table 1. Patients’ age ranges from 34 to
79 years old. There were 40 menopausal patients
(54.7%) whose age ranges from 41 to 58 years old,
and 33 premenopausal patients (45.3%) whose
age ranges from 34 to 40 years old. Patient’s parity
range from 0 to 10 parities, with mean parity was
3 parities. Regarding body mass index, there were
5 underweight patients (6.8%), 22 normal patients
(30.1%), 10 overweight patients (13.6%), 24 obese
grade I patients (32.8%) and 12 obese grade II pa-
tients (16.7%).
Table 1. Distribution of Endometrial Cancer in Dr. Cipto
Mangunkusumo Hospital year 2002-2012.
Demographic Characteristics n = 73 %
Age
• Median 53
• Minimum 34
• Maximum 79
Parities
• Mean 3
• Minimum 0
• Maximum 10
• Nulliparity 22 30.1
Menopause
• Yes 40 54.8
• No 33 45.2
Menopausal Age
• Median 51
• Minimum 41
• Maximum 58
Body Mass Index
• Underweight 5 6.8
• Normal 22 30.1
• Overweight 10 13.6
• Obese I 24 32.8
• Obese II 12 16.7
The distribution of endometrial cancer risk or
recurrence is based on histological type, grade, and
myometrial invasion depth according to ESMO
2009 guidelines.There were low, intermediate and
high risk.5 In this research, low risk found in 12
patients (16.4%), intermediate risk in 27 patients
(36.9%), and high risk 34 patients (46.7%).
Either from D&C or postoperative histopatho-
logical findings showed that Endometrioid Adeno-
carcinoma was the most detected histological type
from, 62 patients and 60 patients (84.9% and
82.1%). From 62 Endometrioid Adenocarcinoma
(84.9%) assessed from D&C, there were 6 patients
(9.6%) which had different final histological type
result. The other D&C histological types showed no
different findings referred to postoperative histo-
logical types. (Table 2) Endometrial cancer grade,
based on D&C histopathological reports, was even-
ly distributed. But, when it comes from postopera-
tive histopathological reports, grade II was the
commonest found (42.4%).
From 73 patients assessed by ultrasonography
examination, showed 23 patients (31.5%) with <
2 myometrial invasion and 50 patients (68.5%)
with ≥ 2 myometrial invasion. There were 27 pa-
tients (36.9%) identified by postoperative patho-
logical finding showed different myometrial inva-
sion result compared to ultrasonography examina-
tion.
Lymph node of < 2 myometrial invasion (based
on ultrasonographic) was evaluated in 12 patients
(52.1%), and only 7 patients (58.3%) with positive
lymph nodes metastases, and 11 patients (47.9%)
without evaluation of lymph node because lym-
phadenectomy was not performed in these pa-
tients. Group with ≥ 2 myometrial invasion had 39
patients (78%) with lymphadenectomy, and 22 pa-
tients (44%) of them had positive lymph node me-
tastases. Eleven patients (22%) were not perfor-
med lymphadenectomy.
From 12 patients with low endometrial cancer
risk that underwent surgery, 3 patients (25%) had
lymphadenectomy with negative pathological results.
Seven out (25.5%) of 27 patients with intermediate
risk were not performed lymphadenectomy. The rest
20 patients of intermediate risk with lymphadenec-
tomy showed 7 patients (35%) had negative lymph
node metastases and 13 patients (65%) had posi-
tive lymph node metastases. Meanwhile, patients
with high risk endometrial cancer showed 20 pa-
tients (58.8%) positive lymph node metastases.
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There were 41.67% of low risk endometrial can-
cer patients, 25.93% of intermediate risk endome-
trial cancer patients, and 29.41% of high risk en-
dometrial cancer patients who had < 2 myometrial
invasion. Whereas 58.33% of low risk patients,
74.07% of intermediate risk patients, and 69.86%
high risk patients had ≥ 2 myometrial invasion.
Low risk endometrial cancer was found 66.6%
confined to uterus. Intermediate risk was found
48.1% confined to uterus and 29.6% metastasize
to pelvic and/or paraaorta lymph nodes. Mean-
while, high risk was found 26.4% confined to
uterus and 50% metastasize to pelvic and/or
paraaorta lymph nodes. All the low risk endo-
metrial cancer patients’ histological type were En-
dometrioid Adenocarcinoma based on postopera-
tive histopathological finding. Endometrioid Ade-
nocarcinoma was the commonest histological type
found in intermediate and high risk endometrial
cancer.
From 12 patients with low risk endometrial can-
cer, there were 11 patients (91.6%) identified with
early stage and 1 patient (8.4%) with advanced
stage endometrial cancer. In intermediate risk
group, there were 14 patients (51.8%) with early
stage and 13 patients (48.2%) with advanced stage.
From high risk group, 12 patients (35.2%) with
early stage and 22 patients (64.8%) with advanced
stage. (Table 3)
DISCUSSION
Endometrial cancer is the most common gyneco-
logical cancer affecting postmenopausal women.
Endometrial cancer most commonly affects women
between 50 - 65 years old.3,17 Those reports were
consistent with our study. However, the difference
between postmenopausal women (54.8%) and
premenopausal women (45.2%) in our study is not
prominent. Menstrual factors, early age at menar-
che and late age at menopause, contribute for de-
velopment of endometrial cancer.3 In this study age
at menarche was not observed, because of lack in-
formation regarding patient’s menarche, especially
data from postmenopausal women group. Patients’
Table 2. Histological Type Comparison between D&C Histological Type and Operative Histological Type.
D&C Histolo-
gical Type
Operative Histological Type
Total
Endometrioid
Adenocarcinoma
Adenosquamous
Carcinoma
Papillary Squa-
mous Carcinoma
Clear Cell
Carcinoma
Carcino-
sarcoma
Endometrioid
Adenocarcinoma
56 1 2 1 2 62
Adenosquamous
Carcinoma
0 1 0 0 0 1
Papillary Squa-
mous Carcinoma
4 0 2 0 0 6
Clear Cell
Carcinoma
0 0 0 2 0 2
Carcinosarcoma 0 0 0 0 2 2
Total 60 2 4 3 4 73
Table 3. Risk of Endometrial Cancer Compared to FIGO Stage.
Risk
FIGO Stage
Total
Stage IA Stage IB Stage II Stage IIIA Stage IIIB Stage IIIC Stage IVA Stage IVB
Low 2 6 3 1 0 0 0 0 12
Intermediate 4 9 1 5 0 8 0 0 27
High 2 6 4 1 0 18 1 2 34
Total 8 21 8 7 0 26 1 2 73
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age in our hospital ranges from 34 - 79 years old,
and the median age is 53 years old. Postmeno-
pausal patients’ age ranges from 51- 58 years old,
and the median is 51 years old. Endometrial cancer
is rare before 40 years old, and in this study only
5 patients under 40 years old were found.3
The other risk factor contributing to endome-
trial cancer is nulliparity which in our study ac-
counted for 30.1% of all patients.3,17 Patients’ pari-
ty ranges from 0 to 10 parities and the mean value
is 3 parities. Nulliparity increase the rate the risk
of endometrial cancer two to three times compared
with non-nulliparity group, and also the risk is de-
creasing with increasing number of children. Infer-
tility also associated with increasing risk of en-
dometrial cancer, such as polycystic ovary syn-
drome.3
Several studies reported that endometrial can-
cer is associated with obesity. Obesity increases en-
dometrial cancer risk 3-fold independently com-
pared to non-obese women.18 Central or upper-
body is more important the measurement pheral
body adiposity specially measurement of central
adiposity after adjustment of BMI, to measure risk
of endometrial cancer.3,19-21 In our report, obese
women (BMI ≥ 25kg/m2) accounted for 39.5% of
all patients which consist of 32.8% obese grade 1
(BMI 25-29.9 kg/m2) and 16.7% obese grade 2
(BMI ≥ 30 kg/m2). The distribution of endometrial
cancer in normal BMI (18.5-24.9 kg/m2) patient
was 30.1% which was not much different in num-
ber with obese grade I patient. Obesity associated
with increasing of endometrial cancer could be bio-
logically explained. Postmenopausal obese women
have higher endogenous level of estrogen com-
pared to lean women due to amortization of an-
drostenedione in adipose tissue.3,18
Based on histopathological finding, approxima-
tely 80% of endometrial cancer were type I (en-
dometrioid) with well to moderate differentiation
which were confined to the uterine corpus at diag-
nosis. High grade type II endometrial cancer ac-
counted for only 15% to 20% of cases.8 In our
study, endometrial cancer type I accounted for
82.1% cases based on D&C results, and 84.9%
based on histopathological finding. There were
9.6% patients diagnosed with endometrial cancer
type I based on D&C result had different postop-
erative histopathological result. It indicates the
D&C examination in our hospital is reliable to de-
termine endometrial cancer histological type.
Meanwhile, differentiation of endometrial cancer
based on postoperative histopathological result
shows 50.6% discrepancy compared to D&C result.
We found that poor differentiation based on D&C
result had the most discrepancy (56.5%) compare
to other differentiation.
Myometrial invasion preoperative assessment
based on ultrasonographic findings is used for de-
termining endometrial cancer risk and planning
surgical procedures.10,22 Our study collected < 2
myometrial invasion based on ultrasonography
findings had 60.8% discrepancy compared to post-
operative histopathological finding. Meanwhile, ≥
2 myometrial invasion based on ultrasonography
had 26% discrepancy. Our finding is consistent
with study conducted by Sato et al, preoperative
myometrial invasion depth based on ultrasonogra-
phy gives inconsistent result compared to postop-
erative histopathological finding.22
Myometrial invasion depth helps clinicians make
decisions during operation to do or not to do lym-
phadenectomy.12,14,23 According to our finding, in
≥ 2 myometrial invasion group (based on ultra-
sonographic examination), only 78% cases were
performed lymphadenectomy procedure. Mean-
while, in < 2 myometrial invasion (postoperative
histopathological finding) group, lymphadenecto-
my was performed in 52.1% cases. It showed lym-
phadenectomy is performed not only based on
myometrial invasion depth, but also based on in-
traoperative assessment of suspicious enlarged
lymphnode.
Endometrial cancer risk were determined by
histological type, grade and myometrial invasion
according to European Society for Medical Onco-
logy (ESMO) 2009.5 This risk classification aim to
determine recurrence, additional procedures (lym-
phadenectomy and/or omentectomy), and adju-
vant therapy.5 There were 16.4% low risk, 37.9%
intermediate risk and 45.7% high risk patients.
Compared to surgical staging, low risk patients had
been confirmed as early stage for 91.6% and as ad-
vanced stage for 8.4%. Intermediate risk cancer
had been confirmed as early stage for 51.8% and
as advanced stage for 48.2%. High risk cancer had
been confirmed as early stage for 35.2% and as ad-
vanced stage for 64.8%.
Based on postoperative histopathological result,
all low risk endometrial cancer patients showed
type I (endometrioid adenocarcinoma) findings,
11.1% of intermediate risk endometrial cancer pa-
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tients showed type II histological findings, and
29.4% of high risk endometrial cancer patients
showed type II histological findings.
Querleu et al, recommends lymphadenectomy is
performed in high risk endometrial cancer, and in
intermediate risk if the tumor in stage IB grade 2
or IA grade 3 with myometrial involvement. Lym-
phadenectomy is not recommended in low risk en-
dometrial cancer.5 In our study, 75% of low risk
endometrial cancer patients’ lymph nodes was not
assessed. Only 25% of them were assessed because
of intraoperative assessment of suspicious enlar-
ged lymph node. However, the lymph node patho-
logical assessment returned with negative result.
Intermediate risk endometrial cancer patient un-
derwent pelvic and/or paraaorta lymphadenecto-
my for 74% cases, only 40% of all the patients had
positive lymph node metastases. From 82.3% high
risk patients underwent pelvic and/or paraaorta
lymphadenectomy, 58.8% had positive lymph node
metastases. According to this finding, high risk en-
dometrial cancer patient had the most positive
lymph node result compared to other risks. More-
over, increasing risk classification showed more
positive lymph node metastases.
Most of the patients were finally diagnosed with
Stage IIIC (35.6%) endometrial cancer. However,
most of the patients were diagnosed with early
stage endometrial cancer (50.6%). Endometrial
cancer risks compared to FIGO stage showed the
higher the risk patient had, the more advanced the
stage were.
CONCLUSION
Most of the patients with endometrial cancer were
preoperatively diagnosed as high risk group. The
commonest of the stage after surgical histopatho-
logical examination were stage IIIC. High risk of re-
currence endometrial cancer showed more posi-
tive lymph node compared to low or intermediate
risk of recurrence. Histopathological findings based
on D&C examination showed inconsistent results
compared to postoperative histopathological find-
ings. Myometrial invasion findings based on ultra-
sonography compared to postoperative findings
showed inconsistent results. Patients with ≥ 2
myometrial invasion had more positive lymph no-
des metastases compared to < 2 myometrial inva-
sion. Endometrial cancer risks compared to FIGO
stage showed the higher the risk patient had, the
more advanced the stage were.
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